Sensus Q3 revenues double to $8.8M; net income $1.2M vs loss; targets >50 IG-SRT deals by year-end

Sensus Healthcare, Inc.

2024-Q3 EPS reported $0.31 revenue$28,741,000

Revenue $8.8M (+127% YoY); net income $1.2M ($0.07 diluted EPS) vs net loss $1.5M ($0.09 loss) in Q3 2023.
Adjusted EBITDA $1.6M vs negative $1.7M; shipped 27 systems (11 in Q3 2023).
Signed 22 IG-SRT units under Fair Deal as of Sep 30; expects >50 by year-end, generating recurring revenue in 2025.
Cash $22.6M, no debt; gross margin improved to 59.3% from 51.0%.
Sold SRT system to Providence Swedish Hospital; strong interest at ASTRO conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.